Depressive DisordersMajor Depressive Disorder (MDD)SchizophreniaPsilocybinAyahuascaMescalineLSD

‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

In a pre-registered meta-analysis of 8 PAT trials (548 patients) and 16 open‑label traditional antidepressant studies (9,751 patients), psychedelic-assisted therapy was not more effective than open‑label antidepressants on the 17‑item Hamilton Depression Rating Scale (difference 0.3 favouring tAD; 95% CI −1.39 to 1.98; p=0.73). This equal‑unblinding comparison emphasises that blinding integrity materially influences apparent treatment effects and that both PAT and tAD produced robust, clinically meaningful improvements.

Authors

  • Balázs Szigeti

Published

OSF Preprints
meta Study

Abstract

Importance

Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding. This effect positively biases results when PAT trials are compared against truly blinded trials.

Objective

This pre-registered meta-analysis investigated the comparative efficacy of PAT and open-label traditional antidepressants (tAD; such as SSRIs and SNRIs) for the treatment of major depression. The rationale is that PAT is effectively always open-label, thus, it is only fair to compare results against open-label tAD trials, so both interventions equally benefit from effects associated with patients knowing the treatment.

Data Sources

PubMed was systematically searched for trials of PAT and open-label tAD for the treatment of major depression without comorbidity in outpatient, non-psychotic adults. 24 of the initially retrieved 619 records met inclusion.Data Extraction and Synthesis: Depression scores were extracted by two independent reviewers; estimates were pooled with both Bayesian and frequentist mixed-effects models. The reporting follows the PRISMA guideline. Main Outcome(s) and Measure(s): Following pre-defined hypothesis, we compared the mean within-arm effect size from baseline to primary endpoint, i.e. the patient improvement, between PAT and open-label tAD trials on the 17-item Hamilton Depression Rating Scale. We also compared the within-arm effect size of blinded vs. open-label trials in both PAT and tAD, to assess the influence of blinding.

Results

In total, 8 PAT trials involving 548 patients and 16 open-label tAD studies involving 9751 patients were included. Contrary to prior hypothesis, PAT was no more effective than open-label tAD treatment (estimated difference: 0.3 favoring open-label tAD; 95% confidence interval: [-1.39, 1.98]; p=0.730). Open-label tAD was associated with better outcomes than blinded treatment (1.3 [0.07, 2.51]; p=0.038), but the same difference was not observed in PAT (0.4 [-2.20, 3.11]; p=0.738).

Conclusions and Relevance

Both tAD and PAT were associated with robust, statistically, and clinically meaningful improvements. However, PAT’s lack of superiority compared to tADs under equal-unblinding conditions highlights the influence of blinding integrity and presents a sobering viewpoint on the treatment’s potential.

Available with Blossom Pro

Research Summary of '‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression'

Introduction

Williams and colleagues frame the analysis around two contrasting pictures of antidepressant efficacy: traditional antidepressants (tADs, primarily SSRIs and SNRIs) have small treatment–placebo (between-arm) differences on the HAMD-17, while psychedelic-assisted therapy (PAT) trials report much larger between-arm effects. The introduction highlights functional unblinding — patients deducing allocation from drug effects — as especially pervasive in PAT trials because of the drugs' intense subjective effects, and notes that unblinding can inflate between-arm estimates. The authors observe limited direct head-to-head evidence comparing PAT and tAD and argue that comparing PAT trials (effectively unblinded) to truly blinded tAD trials creates an unfair advantage for PAT. This pre-registered meta-analysis therefore sets out to compare PAT against open-label tAD trials so both treatments would equally experience effects related to patients knowing their treatment. The primary aim was to compare within-arm change from baseline to primary endpoint (the patient improvement) on the HAMD-17. The authors also planned to compare blinded versus open-label trials within each treatment class to quantify the influence of blinding. The analysis focuses on outpatient, non-psychotic adult major depressive disorder and converts other depression scales into HAMD-17 equivalents for comparability.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (16)

Papers cited by this study that are also in Blossom

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)

656 cited
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)

375 cited
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

Sloshower, J. A., Skosnik, P. D., Safi-Aghdam, H. et al. · Journal of Psychopharmacology (2023)

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer

Lewis, B. R., Garland, E. L., Byrne, K. et al. · Journal of Pain and Symptom Management (2023)

49 cited
Show all 16 references

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.